George Svokos has joined Avet Pharmaceuticals as its CEO and president after serving as a strategic business adviser to numerous global health care companies, according to a Monday announcement from the East Brunswick-based firm.
A rapid growth specialty pharmaceutical company that is focused on the development and distribution of generic medicines in the U.S., is the exclusive U.S. commercial operations of Emcure Ltd.
Svokos’ most recent role was with Emcure. Prior to that, he served as chief operations officer and chief commercial officer at Albany Molecular Research Inc. Svokos also spent nearly 35 years at Teva Pharmaceutical Industries Ltd. in a number of senior leadership roles.
“George Svokos is an industry veteran with deep and varied experience in the global pharmaceutical industry and specific expertise in the U.S. generic market, all of which will be an asset to our team at Avet,” Marvin Samson, chairman of the board of directors at Avet, stated. “The board of directors is confident that George’s leadership, vision and track record for operational excellence will drive forward Avet’s business and our aspiration to serve as a leader in bringing generic medications to patients in the U.S. market.”
